Literature DB >> 8827454

Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas.

H Muramatsu1, X J Song, N Koide, H Hada, T Tsuji, K Kadomatsu, T Inui, T Kimura, S Sakakibara, T Muramatsu.   

Abstract

Midkine (MK) is a growth factor that promotes neurite outgrowth and survival of neurons, and enhances the plasminogen activator in endothelial cells. A highly sensitive enzyme-linked immunoassay for MK was developed, involving affinity-purified anti-MK antibodies, their biotinylated form, and avidin-beta-galactosidase. The amount of bound avidin-beta-galactosidase was determined using a fluorogenic substrate, 4-methylumbelliferyl-beta-D-galactoside. This method allowed the detection of human and mouse MK in the range of 50 pg-10 ng. Pleiotrophin, which is related to MK in its amino acid sequence, did not show any cross reactivity. Employing this method, the MK levels in the developing mouse brain were determined. The MK level was 2 micrograms/g of wet tissue on the 12th day of gestation, and then steadily decreased during embryogenesis and postnatal development to 30 ng/g two months after birth. The assay method can also be applied to serum samples. Although the MK levels in the sera of normal human subjects were low or undetectable, 0.6-8 ng/ml of MK was detected in samples in the majority of cases of hepatocellular carcinomas.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827454     DOI: 10.1093/oxfordjournals.jbchem.a021364

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  11 in total

1.  The advances of Midkine with peripheral invasion in pancreatic cancer.

Authors:  Jun Yao; Wen-Yao Li; She-Gan Gao
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

Review 2.  Midkine (MDK) growth factor: a key player in cancer progression and a promising therapeutic target.

Authors:  Panagiota S Filippou; George S Karagiannis; Anastasia Constantinidou
Journal:  Oncogene       Date:  2019-12-04       Impact factor: 9.867

Review 3.  Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases.

Authors:  Takashi Muramatsu
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

4.  Midkine as a factor to counteract the deposition of amyloid β-peptide plaques: in vitro analysis and examination in knockout mice.

Authors:  Hisako Muramatsu; Katsunori Yokoi; Lan Chen; Keiko Ichihara-Tanaka; Terutoshi Kimura; Takashi Muramatsu
Journal:  Int Arch Med       Date:  2011-01-12

Review 5.  Midkine: a promising molecule for drug development to treat diseases of the central nervous system.

Authors:  Takashi Muramatsu
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

6.  Serum midkine levels are increased in patients with various types of carcinomas.

Authors:  S Ikematsu; A Yano; K Aridome; M Kikuchi; H Kumai; H Nagano; K Okamoto; M Oda; S Sakuma; T Aikou; H Muramatsu; K Kadomatsu; T Muramatsu
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

7.  Diagnostic impact of high serum midkine level in patients with gastric cancer.

Authors:  Masaaki Ito; Yoko Oshima; Satoshi Yajima; Takashi Suzuki; Tatsuki Nanami; Fumiaki Shiratori; Kimihiko Funahashi; Hideaki Shimada
Journal:  Ann Gastroenterol Surg       Date:  2019-01-08

8.  Diagnostic accuracy of midkine on hepatocellular carcinoma: A meta-analysis.

Authors:  Bo-Han Zhang; Bo Li; Ling-Xiang Kong; Lv-Nan Yan; Jia-Yin Yang
Journal:  PLoS One       Date:  2019-10-10       Impact factor: 3.240

9.  Midkine as a prognostic biomarker in oral squamous cell carcinoma.

Authors:  K Ota; H Fujimori; M Ueda; S Shiniriki; M Kudo; H Jono; Y Fukuyoshi; Y Yamamoto; H Sugiuchi; H Iwase; M Shinohara; Y Ando
Journal:  Br J Cancer       Date:  2008-08-19       Impact factor: 7.640

10.  Midkine: a novel prognostic biomarker for cancer.

Authors:  Hirofumi Jono; Yukio Ando
Journal:  Cancers (Basel)       Date:  2010-04-20       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.